CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype

CONCLUSIONS: iCCA patients with higher NOTCH1/HES1/THY1 expression have the worst prognosis, but they are more likely to benefit from Notch signaling inhibition. These findings represent the scientific rationale for testing NOTCH1 inhibitors in clinical trials, taking the first step toward precision medicine for iCCA.PMID:35172861 | DOI:10.1186/s13046-022-02283-8

Source: Cell Research - February 17, 2022 Category: Cytology Authors: Serena Mancarella Grazia Serino Isabella Gigante Antonio Cigliano Silvia Ribback Paola Sanese Valentina Grossi Cristiano Simone Raffaele Armentano Matthias Evert Diego F Calvisi Gianluigi Giannelli Source Type: research